Arovella Therapeutics (ASX:ALA) has reinforced its commitment to sustainable business practices with the release of its fourth Environmental, Social, and Governance (ESG) Report, outlining progress in governance, environmental responsibility, social impact, and long-term value creation.
The company stated that ESG principles remain central to its strategy, aligning with the United Nations' Sustainable Development Goals and the World Economic Forum’s Stakeholder Capitalism Metrics. By embedding these standards into governance and performance management, Arovella aims to ensure transparency and accountability across its operations.
Arovella reported no incidents of bribery, corruption, whistleblower complaints, or political donations over the past three years, reflecting its adherence to strict anti-corruption laws and internal codes of conduct. Its Board continues to review and strengthen risk oversight, with annual assessments of the company’s risk management framework.
Though Arovella operates with a small workforce and modest footprint, it offset 40.03 tonnes of carbon emissions from air travel in FY2025 by purchasing carbon credits. The company has committed to maintaining full offsets for employee flights in the years ahead.
The report highlighted strong performance in diversity and inclusion, with 40 per cent female directors and equal gender representation at the senior executive level. Employees also undertook an average of 34.5 hours of professional development during FY2025, exceeding the target of 22 hours. Importantly, Arovella achieved pay parity in like-for-like roles, though the company noted that average female salaries were 78 per cent of male salaries due to role distribution.
The company also underscored its positive workplace record, reporting no workplace fatalities, injuries, or incidents of discrimination or harassment. Additionally, a company-wide charity fundraiser engaged all staff, raising $7,813 for local community initiatives.
Arovella’s financial contribution to innovation remains significant, with $8 million spent on R&D in FY2025, representing 71 per cent of overall expenses. This emphasis underscores its mission to develop novel therapies while maintaining a culture of ethical and sustainable business.
The company stated that it would continue to refine its ESG disclosures, expand reporting on stakeholder mapping, and maintain transparency regarding issues material to its business. “Integrating ESG into every aspect of our operations is not only about responsibility but about ensuring sustainable growth and long-term value creation,” the report noted.<